Capromorelin
A Phase II clinical trial investigated the effects of capromorelin on body composition and functional performance in healthy elderly people. At 12 months, capromorelin significantly increased lean body mass and the ability to climb stairs compared to placebo. However, this study was terminated early because results at 12 months were not considered a continuation of this study [43]. As the aging process is not considered a pathological condition by the FDA, capromorelin must offer excellent results, as a survival benefit in this case. population or be applied to other clinical indications. Capromorelin has so far only been approved by the FDA as a short-term therapeutic option for improving appetite in anorexic dogs.